Macrolide resistance in bacteremic pneumococcal disease: Implications for patient management

被引:116
作者
Daneman, N.
McGeer, A.
Green, K.
Low, D. E.
机构
[1] Mt Sinai Hosp, Shared Dept Microbiol, Toronto, ON M5G 1X5, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
关键词
D O I
10.1086/505871
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Despite pneumococcal antibiotic resistance rates in excess of 25%, macrolides remain first-line agents for the treatment of community-acquired pneumonia. Methods. Prospective, population-based surveillance was conducted to identify cases of pneumococcal bacteremia in Toronto and Peel, Canada, between 2000 and 2004. "Macrolide failures" were defined as cases of bacteremia occurring during outpatient treatment with macrolide antibiotics or within 2 days after treatment. Macrolide susceptibility was determined according to Clinical Laboratory Standards Institute guidelines; common macrolide resistance mechanisms were determined by genotyping. Results. During the 5 years of surveillance, there were 1696 episodes of pneumococcal bacteremia (8.5 cases/100,000 population/year), of which 60 (3.5%) were failures of outpatient macrolide therapy. Resistant isolates were more common among cases of bacteremia after failure of macrolide therapy (37 [64%] of 58 cases) than among cases of bacteremia after failure of nonmacrolide antibiotics (16 [22%] of 74 cases; P < .001) or cases of bacteremia that occurred without prior antibiotic therapy (193 [12%] of 1569 cases; P < .001). Macrolide failures were significantly more common among cases of pneumococcal bacteremia with isolates exhibiting an erythromycin MIC of 1 mu g/mL than among isolates exhibiting MICs <= 0.25 mu g/mL (3 [38%] of 8 cases vs. 21 [1.5%] of 1394 cases of bacteremia; P < .001). Increases in the MIC to 1 mg/mL were not associated with further increases in the likelihood of macrolide failure. Low-level resistance conferred by mefA and high-level resistance conferred by ermB were equally overrepresented among macrolide failures. Conclusions. Macrolide resistance contributes to an increased risk of macrolide failure, irrespective of the underlying resistance mechanism or of the degree of elevation in erythromycin MIC.
引用
收藏
页码:432 / 438
页数:7
相关论文
共 24 条
  • [1] Pneumococcal macrolide resistance - myth or reality?
    Amsden, GW
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (01) : 1 - 6
  • [2] PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA
    AUSTRIAN, R
    GOLD, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1964, 60 (05) : 759 - +
  • [3] Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
  • [4] MICROBIAL ETIOLOGY OF ACUTE PNEUMONIA IN HOSPITALIZED-PATIENTS
    BATES, JH
    CAMPBELL, GD
    BARRON, AL
    MCCRACKEN, GA
    MORGAN, PN
    MOSES, EB
    DAVIS, CM
    [J]. CHEST, 1992, 101 (04) : 1005 - 1012
  • [5] Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study
    ClavoSanchez, AJ
    GironGonzalez, JA
    LopezPrieto, D
    CanuetoQuintero, J
    SanchezPorto, A
    VergaraCampos, A
    MarinCasanova, P
    CordobaDona, JA
    [J]. CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) : 1052 - 1059
  • [6] Time to resolution of morbidity: An endpoint for assessing the clinical cure of community-acquired pneumonia
    Daifuku, R
    Movahhed, H
    Fotheringham, N
    Bear, MB
    Nelson, S
    [J]. RESPIRATORY MEDICINE, 1996, 90 (10) : 587 - 592
  • [7] Antimicrobial resistance among Streptococcus pneumoniae in the United States:: Have we begun to turn the corner on resistance to certain antimicrobial classes?
    Doern, GV
    Richter, SS
    Miller, A
    Miller, N
    Rice, C
    Heilmann, K
    Beekmann, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (02) : 139 - 148
  • [8] Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance
    Farrell, DJ
    Jenkins, SG
    Brown, SD
    Patel, M
    Lavin, BS
    Klugman, KP
    [J]. EMERGING INFECTIOUS DISEASES, 2005, 11 (06) : 851 - 858
  • [9] Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia
    File, TM
    Garau, J
    Blasi, F
    Chidiac, C
    Klugman, K
    Lode, H
    Lonks, JR
    Mandell, L
    Ramirez, J
    Yu, V
    [J]. CHEST, 2004, 125 (05) : 1888 - 1901
  • [10] Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management
    Fuller, JD
    McGeer, A
    Low, DE
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (12) : 780 - 788